Management of metastatic renal cell carcinoma: Current trends

Expert Review of Molecular Diagnostics

Volumn 9, Issue 1, 2009, Pages 75-83

  Mohammed, Aza ^a,b   Shergill, Iqbal ^c   Little, Brian ^b  

^a Ayr Hospital ^*  (United Kingdom)

^b AYR HOSPITAL   (United Kingdom)

^c KING GEORGE HOSPITAL   (United Kingdom)

Author keywords

Cytokines; Kidney cancer; Management; Metastasis; Tyrosine kinase

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BEVACIZUMAB; CYTOKINE; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANEMIA; ARTERIAL THROMBOEMBOLISM; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISTANT METASTASIS; DRUG EFFICACY; DRUG TARGETING; DYSPNEA; FATIGUE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPEBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; NEUTROPENIA; PERIPHERAL EDEMA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEINURIA; RASH; REVIEW; STOMATITIS; THROMBOCYTOPENIA;

ANIMALS; CARCINOMA, RENAL CELL; CYTOKINES; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS;

EID: 58149268839     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.9.1.75     Document Type: Review

References (61)

1. Mancuso A, Sternberg CN. New treatment approaches in metastatic renal cell carcinoma. Curr. Opin. Urol. 16(5), 337-341 (2006).
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 58(2), 71-96 (2008)
3. Hutson TE, Figlin RA. Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park, NY) 21(10), 1175-1180 (2007)
4. Zisman A, Belldegrun AS, Figlin RA. Urinary tract cancers. In: Manual of Clinical Oncology (5th Edition). Casciato DA (Ed.). Lippincott Williams & Wilkins, PA, USA, 295-320 (2004).
5. Motzer RJ, Russo P, Nanus DM, Berg WJ. Renal cell carcinoma. Curr. Probl. Cancer 21(4), 185-232 (1997).
6. Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs 67(9), 1257-1264 (2007).
7. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial Sloan-Kettering cancer center experience. Clin. Cancer Res. 10(18 Pt 2), 6302S-6303S (2004).
8. Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23(4), 832-841 (2005).
9. Robson CJ. Radical nephrectomy for renal cell carcinoma. J. Urol. 89, 37-42 (1963).
10. Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J. Urol. 167(3), 1295-1298, (2002).
11. Schafhauser W, Ebert A, Brod J, Petsch S, Schrott KM. Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy. Anticancer Res. 19(2C), 1573-1578, (1999).
12. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345(23), 1655-1659 (2001) • One of two studies demonstrating the effectiveness of cytoreductive surgery in improving survival in patients with metastatic renal cell carcinoma (mRCC).
13. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon ? alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286), 966-970 (2001).
14. Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N. Engl. J. Med. 345 (23), 1711-1712 (2001)
15. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J. Clin. Oncol. 16(6), 2261-2266 (1998).
16. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313(23), 1485-1492 (1985).
17. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N. Engl. J. Med. 338(18), 1272-1278 (1998).
18. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21(16), 3127-3132 (2003).
19. McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23(1), 133-141 (2005). • Trial demonstrating the efficacy of high-dose IL-2 on managing patients with mRCC compared to subcutaneous IL-2 and IFN-α.
20. Negrier S, Perol D, Ravaud A et al. Medroxyprogesterone, interferon α-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110(11), 2468-2477 (2007)
21. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. (1), CD001425 (2005).
22. Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 105(1), 31-57 (1995).
23. Basche B. A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage. JAMA 295(21), 2537-2538 (2006).
24. Melmon KL, Rosen SW. Lindau's disease. Review of the literature and study of a large kindred. Am. J. Med. 36, 595-617 (1964).
25. Linehan WM, Vasselli J, Srinivasan R et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin. Cancer Res. 10(18 Pt 2), 6282S-6829S (2004). •• Provides an excellent review on the molecular biology of renal carcinoma and the rule of VHL gene mutation in the pathogenesis of renal cell carcinoma.
26. Izzedine H, Billemont B, Thibault F, Rixe O. New challenges in kidney cancer therapy: sunitinib. Ann. Oncol. 18(Suppl. 9), ix83-ix86 (2007).
27. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 23(5), 1028-1043 (2005).
28. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl Acad. Sci. USA 97(19), 10430-10435 (2000).
29. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19(3), 843-850 (2001).
30. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349(5), 427-434 (2003).
31. Bukowski RM, Kabbinavar FF, Figlin RA et al. Randomized Phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol. 25(29), 4536-4541 (2007)
32. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370(9605), 2103-2111 (2007).
33. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon α compared with interferon α monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. (2008) (Epub ahead of print).
34. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 7(3), 193-201 (2004).
35. Granger JP, Alexander BT. Abnormal pressure-natriuresis in hypertension: role of nitric oxide. Acta Physiol. Scand. 168, 161-168 (2000).
36. Ostendorf T, Kunter U Eitner F. VEGF mediates glomerular endothelial repair. J. Clin. Invest. 104, 913-923 (1999)
37. Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
38. Kabbinvar FF, Schulz J, McLeod M. Addition of bevacizumab to bolus 5FU/leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J. Clin. Oncol. 23, 3697-3705 (2005).
39. Scappaticci FA, Fehrenbacher L, Cartwright T. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol. 91, 173-180 (2005).
40. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24(1), 25-35 (2006).
41. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(1), 16-24 (2006). • One of two Phase II trials that showed the effectiveness of sunitinib in the management of mRCC.
42. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21), 2516-2524 (2006).
43. Rosenberg JE, Motzer RJ, Michaelson MD et al. Sunitinib therapy for patients with metastatic renal cell carcinoma (mRCC). Updated results of two Phase II trials and prognostic factor analysis for survival. Proc. Am. Soc. Clin. Oncol. 25, 5095 (2007)
44. Harshman L, Srinivas S. Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer. Onkologie 31(8-9), 432-433 (2008).
45. Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 26(22), 3743-3748 (2008).
46. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
47. Grünwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 30(10), 519-524 (2007)
48. Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 148(2), 90-92 (1974).
49. Sutent. Summary of product characteristics. Pfizer Inc, NY, USA (2008).
50. Hiles JJ, Kolesar JM. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am. J. Health Syst. Pharm. 65(2), 123-131 (2008)
51. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 2505-2512 (2006).
52. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92(3), 205-216 (2000).
53. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007). •• Largest double-blinded study in the history of mRCC, which showed the effectiveness of sorafenib in the management of mRCC compared to the placebo.
54. Gollob JA, Rathmell WK, Richmond TM et al. Phase II trial of sorafenib plus interferon α-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J. Clin. Oncol. 25(22), 3288-3295 (2007).
55. Eisen T, Oudard S, Szczylik C et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J. Natl Cancer Inst. 100(20), 1454-1463 (2008).
56. Schrader AJ, Hofmann R. Metastatic renal cell carcinoma: recent advances and current therapeutic options. Anticancer Drugs 19(3), 235-245 (2008).
57. Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22(5), 909-918 (2004).
58. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007).
59. Jac J, Giessinger S, Khan M,Willis J, Chiang S, Amato R. A Phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC). J. Clin. Oncol. 25 (2007) (Abstract 5107).
60. Amato RJ, Misellati A, Khan M, Chiang S. A Phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J. Clin. Oncol. 24(Suppl.) (2006) (Abstract 4530).
61. Patard JJ. Tyrosine kinase inhibitors in clinical practice: patient selection. Eur. Urol. Suppl. 7(9) 601-609 (2008).